APPLICATION
ANDA204806
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-25
LATEST ACTION
2025-06-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
ATAZANAVIR SULFATEPrescription
ATAZANAVIR SULFATE EQ 200MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEPrescription
ATAZANAVIR SULFATE EQ 100MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEPrescription
ATAZANAVIR SULFATE EQ 300MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEPrescription
ATAZANAVIR SULFATE EQ 150MG BASE · CAPSULE · ORAL
Approval history
2025-06-26Labeling · Supplement 13 · standardAP
2024-06-21Labeling · Supplement 12 · standardAP
2024-06-21Labeling · Supplement 8 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.